Detalles de la búsqueda
1.
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
J Immunol;
206(7): 1454-1468, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33674445
2.
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Nat Chem Biol;
11(7): 525-31, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26006010
3.
Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).
Bioorg Med Chem Lett;
27(3): 632-635, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28025004
4.
Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.
Bioorg Med Chem Lett;
25(2): 367-71, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25466710
5.
Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
Bioorg Med Chem Lett;
23(5): 1486-92, 2013 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23352510
6.
Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
Bioorg Med Chem Lett;
22(13): 4296-302, 2012 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22672799
7.
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
J Med Chem;
65(7): 5300-5316, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302767
8.
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Bioorg Med Chem Lett;
21(11): 3452-6, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21515047
9.
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.
Immunohorizons;
5(7): 581-589, 2021 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326199
10.
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
J Pharmacol Exp Ther;
327(3): 610-9, 2008 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-18776065
11.
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
J Med Chem;
60(15): 6516-6527, 2017 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28665128
12.
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.
Mol Cancer Ther;
16(12): 2668-2676, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28978721
13.
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
J Med Chem;
49(5): 1562-75, 2006 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-16509574
14.
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development.
Curr Top Med Chem;
5(10): 1017-29, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16178744
15.
Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis.
J Med Chem;
58(1): 512-6, 2015 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24712864
16.
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
J Med Chem;
46(22): 4702-13, 2003 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-14561090
17.
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
J Med Chem;
57(6): 2683-91, 2014 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24520947
18.
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.
J Med Chem;
56(4): 1677-92, 2013 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-23350847
19.
Rational design of highly selective spleen tyrosine kinase inhibitors.
J Med Chem;
55(23): 10414-23, 2012 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23151054
20.
Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.
J Med Chem;
55(17): 7686-95, 2012 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-22877085